Improved Outcomes with Low-Dose Hypomethylating Agent Plus Venetoclax As Post-Transplant Maintenance in Patients Undergoing Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Myeloid Malignancies
Puntos clave
Improved outcomes in patients with myeloid malignancies receiving low-dose hypomethylating agents with venetoclax post-transplant.
A notable 30% reduction in relapse rates was observed among treated patients compared to historical controls.
Assessment of treatment effectiveness employed a retrospective cohort analysis of post-transplant outcomes.
Highlights the importance of innovative maintenance therapies in enhancing survival after hematopoietic stem cell transplantation.
Mejor resultados con un agente hipometilante a baja dosis más venetoclax como mantenimiento post-transplante en pacientes que se someten a trasplante de células madre hematopoyéticas alogénico con acondicionamiento de intensidad reducida para malignidades mieloides. | Synapse